Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCA-0321
- Development stage
- Phase 1
- Lead developer
- Lycia Therapeutics
- Modality
- Lysosome-Targeting Antibody Chimeras (LYTAC / CataLYTAC) → Antibody-Based Degraders → Antibody-Based Therapeutics
01
Overview
LCA-0321 is a lysosome-targeted chimera (LYTAC) degrader developed by Lycia Therapeutics. It is designed to specifically bind and rapidly eliminate disease-causing anti-thyroid-stimulating hormone receptor (TSHR) autoantibodies, which are the underlying cause of Graves' disease and its extrathyroidal manifestations such as thyroid eye disease (TED). By targeting these pathogenic autoantibodies for lysosomal degradation, LCA-0321 aims to restore normal thyroid function without causing general immunosuppression. Preclinical data have shown that it can selectively deplete patient-derived TSHR autoantibodies in both mice and human cells[3][5][6][8].
02
Targets
IGF2R (Cation-independent mannose-6-phosphate receptor)
Beyond the preview
Go deeper on LCA-0321.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCA-0321.